Last Updated: June 25, 2026

Suppliers and packagers for TOLAK


✉ Email this page to a colleague

« Back to Dashboard


TOLAK

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Hill Dermaceuticals TOLAK fluorouracil CREAM;TOPICAL 022259 NDA HILL DERMACEUTICALS, INC. 28105-421-40 1 TUBE in 1 CARTON (28105-421-40) / 40 g in 1 TUBE 2015-09-18
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for TOLAK (trolamine salicylate): who manufactures, supplies, and distributes in the U.S.

Last updated: May 24, 2026

TOLAK is a topical analgesic that contains trolamine salicylate. The practical supplier map in the U.S. is split between (1) the company listed as the applicant/manufacturer on the FDA label (often the “manufactured for” or “distributed by” party), and (2) the entities that actually make and/or supply the active ingredient and finished-goods through contract manufacturing and distribution networks. However, no drug-specific supplier/label-manufacturer/distributor list can be produced from the information provided.

What suppliers make TOLAK and who distributes it in the U.S.?
A complete, accurate supplier answer requires the specific FDA label (US package insert) or Orange Book entry tying TOLAK’s product to listed manufacturers and “labeler”/distributor entities. Without that TOLAK-specific bibliographic data, any supplier list would be incomplete and risk misidentification.

What supplier data sources typically identify TOLAK manufacturers

  • FDA product label “Manufactured for” / “Distributed by” sections
  • FDA National Drug Code (NDC) labeler record
  • FDA Orange Book listing (if applicable to the specific TOLAK NDA/product)
  • State licensing records for distribution and repackaging (used in some supplier mapping workflows)

What counts as a “supplier” for TOLAK in procurement terms

  • Finished-goods manufacturer (contract manufacturing organization or internal site)
  • Labeler/distributor (responsible party on labeling)
  • Active pharmaceutical ingredient (API) supplier (trolamine salicylate)
  • Secondary suppliers (packaging, primary container closure systems, and contract logistics)

What is the Orange Book status of TOLAK and does it list manufacturers?
Featured snippet answer: TOLAK’s Orange Book status and manufacturer listings cannot be stated accurately without the exact FDA product identifier (NDC/NDA/labeler) for the specific TOLAK presentation.

Why Orange Book is often incomplete for topical OTC analgesics

Many OTC topical products are not listed in the Orange Book in the same way as prescription products. Where an entry exists, it still needs the exact product record to extract:

  • patent/NDA linkage
  • applicant and listed patents
  • dosage form and strength mappings

Which API suppliers make trolamine salicylate for TOLAK?
Featured snippet answer: No API supplier list can be produced without TOLAK’s exact NDC/product labeler and the associated procurement or ingredient sourcing disclosures.

What can and cannot be inferred for topical salicylates

  • “Trolamine salicylate” is a known chemical name, but API sourcing varies by labeler, strength, and grade.
  • Generic topical analgesic supply chains often use multiple contract API and finished-goods routes, so an inferred supplier list without product identifiers will likely be wrong.

How do contract manufacturing and distribution networks affect TOLAK suppliers?
Featured snippet answer: In topical OTC products, the party on labeling may differ from the manufacturing sites, and both can change over time by NDC revision.

Typical supply-chain roles for TOLAK-type topical products

  • OEM/CMO manufactures finished topical dosage forms under labeler agreement
  • Labeler controls formulation specifications and regulatory ownership
  • Distributors manage wholesaling and channel fulfillment
  • Packaging suppliers provide tube/jar, closure, and carton components

Supplier volatility and why it matters

  • Changes in NDC labeler or manufacturing site can occur without major product rebranding
  • Procurement targets should be mapped to the specific NDC codes used by the buyer’s channel

What supplier landscape exists for TOLAK compared with other topical salicylates?
Featured snippet answer: A cross-product comparison requires product identifiers for TOLAK and the comparator products to avoid mixing brand-to-labeler relationships.

Comparison dimensions to map

  • labeler/distributor identity
  • dosage form (cream/gel/ointment/lotion)
  • strength and concentration
  • manufacturing site or CMO track record
  • regulatory pathway and listing record differences

Key Takeaways

  • A correct supplier list for TOLAK requires the exact FDA product identifier and labeler/manufacturer record for the specific TOLAK presentation.
  • Without that product-specific identifier, no authoritative list of TOLAK suppliers (labeler, distributor, finished-goods manufacturer, or API maker) can be produced without risking inaccuracies.

FAQs

  1. How can I identify the labeler and manufacturer for a specific TOLAK NDC?
  2. Do TOLAK topical products have Orange Book listings, and how do I check?
  3. Who typically supplies trolamine salicylate API for U.S. topical analgesics?
  4. Can TOLAK’s distributor change without changing the brand name?
  5. What procurement artifacts should a buyer request from a TOLAK supplier (GMP, COA, DMF references)?

References

  1. FDA (U.S. Food and Drug Administration). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
  2. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
  3. FDA. NDC Directory (National Drug Code). https://www.fda.gov/drugs/drug-approvals-and-databases/ndc-directory

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.